

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name ☒ Organization/Lobbying Firm ☐ Self Employed Individual

Timmons and Company

2. Address ☐ Check if different than previously reported

Address1 1875 Eye Street, NW

Address2 Suite 400

City Washington

State DC

Zip Code 20006

Country USA

3. Principal place of business (if different than line 2)

City

State

Zip Code

Country

4a. Contact Name

b. Telephone Number

c. E-mail

5. Senate ID#

MICHAEL J. BATES

☐ International Number

(202) 331-1760

ks@timmonsandco.com

38164-36

7. Client Name

☐ Self

☐ Check if client is a state or local government or instrumentality

6. House ID#

AMERICAN MEDICAL ASSOCIATION

309740001

TYPE OF REPORT

8. Year 2009

Q1 (1/1 - 3/31) ☐

Q2 (4/1 - 6/30) ☒

Q3 (7/1-9/30) ☐

Q4 (10/1 - 12/31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐

Termination Date

11. No Lobbying Issue Activity ☐

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$5,000

☐

\$5,000 or more

☒

\$ \$ 100,000.00

Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$5,000

☐

\$5,000 or more

☐

\$

14. REPORTING

Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature Filed Electronically

Date 07/10/2009

Printed Name and Title Michael J. Bates, Vice President and General Counsel

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

MMM

MEDICARE/MEDICAID

(one per page)

16. Specific lobbying issues

H.R. 1384 - To amend part B of title XVIII of the Social Security Act to remove limiting charges under the Medicare Program for non-participating physicians with beneficiary notice and to preempt State laws that prohibit balance billing.

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Michael J	Bates			<input type="checkbox"/>
Michelle	Bright			<input type="checkbox"/>
Erin	Graefe			<input type="checkbox"/>
Bryce L	Harlow			<input type="checkbox"/>
Chuck	Jones		Legislative Asst - Office of Senator Tom Carper	<input checked="" type="checkbox"/>
Ginger	Loper			<input type="checkbox"/>
Marty	Paone			<input type="checkbox"/>
William E	Timmons	Jr.		<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

Michael J. Bates, Vice President and General Counsel

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

TAX

TAXATION/INTERNAL REVENUE CODE

(one per page)

16. Specific lobbying issues

H.R. 1087 - To amend the Internal Revenue Code of 1986 to increase the deduction under section 179 for the purchase of qualified health care information technology by medical care providers, and for other purposes.

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Michael J	Bates			<input type="checkbox"/>
Michelle	Bright			<input type="checkbox"/>
Erin	Graefe			<input type="checkbox"/>
Bryce L	Harlow			<input type="checkbox"/>
Chuck	Jones		Legislative Asst - Office of Senator Tom Carper	<input checked="" type="checkbox"/>
Ginger	Loper			<input type="checkbox"/>
Marty	Paone			<input type="checkbox"/>
William E	Timmons	Jr.		<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

Michael J. Bates, Vice President and General Counsel

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

TORTTORTS

(one per page)

16. Specific lobbying issues

H.R. 1086 - To improve patient access to health care services and provide improved medical care by reducing the excessive burden the liability system places on the health care delivery system.

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Michael J	Bates			<input type="checkbox"/>
Michelle	Bright			<input type="checkbox"/>
Erin	Graefe			<input type="checkbox"/>
Bryce L	Harlow			<input type="checkbox"/>
Chuck	Jones		Legislative Asst - Office of Senator Tom Carper	<input checked="" type="checkbox"/>
Ginger	Loper			<input type="checkbox"/>
Marty	Paone			<input type="checkbox"/>
William E	Timmons	Jr.		<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

Michael J. Bates, Vice President and General Counsel

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

HCRHEALTH ISSUES

(one per page)

16. Specific lobbying issues

Omnibus health Care Reform legislation to be introduced.
S. 1213 - A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Patient-Centered Outcomes Research Trust Fund, and for other purposes.

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Michael J	Bates			<input type="checkbox"/>
Michelle	Bright			<input type="checkbox"/>
Erin	Graefe			<input type="checkbox"/>
Bryce L	Harlow			<input type="checkbox"/>
Chuck	Jones		Legislative Asst - Office of Senator Tom Carper	<input checked="" type="checkbox"/>
Ginger	Loper			<input type="checkbox"/>
Marty	Paone			<input type="checkbox"/>
William E	Timmons	Jr.		<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

Michael J. Bates, Vice President and General Counsel

S. 1259 - A bill to protect all patients by prohibiting the use of data obtained from comparative effectiveness research to deny coverage of items or services under Federal health care programs and to ensure that comparative effectiveness research accounts for advancements in personalized medicine and differences in patient treatment response.

H. R. 2520 - To provide comprehensive solutions for the health care system of the United States, and for other purposes.